
## Barbara Ruggiero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9308691/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comment on: European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis—the SHARE initiative. Rheumatology, 2021, 60, e179-e180.	1.9	1
2	Results of the PROPINE randomized controlled study suggest tapering of prednisone treatment for relapses of steroid sensitive nephrotic syndrome is not necessary in children. Kidney International, 2021, 99, 475-483.	5.2	14
3	IgM on the surface of T cells: a novel biomarker of pediatric-onset systemic lupus erythematosus. Pediatric Nephrology, 2021, 36, 909-916.	1.7	2
4	Functional Magnetic Resonance Imaging Versus Kidney Biopsy to Assess Response to Therapy in Nephrotic Syndrome: A Case Report. Kidney Medicine, 2020, 2, 804-809.	2.0	2
5	Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness. BMJ Case Reports, 2020, 13, e232896.	0.5	32
6	Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. American Journal of Kidney Diseases, 2019, 74, 338-350.	1.9	17
7	C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. American Journal of Kidney Diseases, 2019, 74, 224-238.	1.9	45
8	Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. Diabetes, Obesity and Metabolism, 2019, 21, 1177-1190.	4.4	14
9	Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 27-40.	11.4	24
10	Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 2729-2737.	6.1	125
11	Minimal Change Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 332-345.	4.5	336
12	The Role of Angiotensin II in Parietal Epithelial Cell Proliferation and Crescent Formation in Glomerular Diseases. American Journal of Pathology, 2017, 187, 2441-2450.	3.8	20
13	Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial. Diabetes, 2017, 66, 75-86.	0.6	66
14	Another Piece of the Puzzle of Podocyte B7-1 Expression: Lupus Nephritis. Nephron, 2016, 133, 129-138.	1.8	8
15	Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?. American Journal of Physiology - Renal Physiology, 2016, 310, F335-F341.	2.7	45
16	Outcome of childhood-onset full-house nephropathy. Nephrology Dialysis Transplantation, 2016, 32, gfw230.	0.7	19
17	B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome. Journal of the American Society of Nephrology: JASN, 2016, 27, 1811-1822.	6.1	174
18	B7–1 Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2016, 27, 999-1005.	6.1	30

BARBARA RUGGIERO

#	Article	IF	CITATIONS
19	Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2015, 26, 2545-2558.	6.1	280
20	Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome. Journal of the American Society of Nephrology: JASN, 2014, 25, 850-863.	6.1	199
21	Refractory focal segmental glomerulosclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximab. BMJ Case Reports, 2014, 2014, bcr2014205507-bcr2014205507.	0.5	8
22	Lupus nephritis in children and adolescents: results of the Italian Collaborative Study. Nephrology Dialysis Transplantation, 2013, 28, 1487-1496.	0.7	49
23	Rituximab in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 1416-1425.	6.1	252
24	Usefulness of skin immunofluorescence for distinguishing SLE from SLE-like renal lesions: a pilot study. Pediatric Nephrology, 2011, 26, 77-83.	1.7	6
25	Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients. Rheumatology, 2010, 49, 2281-2289.	1.9	78